Study register · detail
Harm
GRADE
Low
224 citations
Samplen = 229 Pat.
Duration10 years follow-up after first…
EndpointPsychotic symptoms
Blindingn.a.
DesignProspektive Kohortenstudie (10 Jahre Follow-up)
Key finding
Cannabis use is bidirectionally associated with a less favorable course of psychotic symptoms and with earlier psychosis onset.
Summary
n=229 patients with schizophrenia spectrum disorder, 10-year follow-up after first admission; lifetime prevalence of cannabis use 66,2%; cannabis use bidirectionally associated with psychotic symptoms (mixed-effects model, p<0.05 after adjustment for sex, age, SES, other substances, antipsychotics); lifetime use associated with earlier psychosis onset.
P
PopulationPatients with schizophrenia spectrum disorder after first psychiatric hospitalization, n=229
I
InterventionCannabis use (observed/naturalistic, self-report at five measurement time points)
O
OutcomeChanges in cannabis use associated with changes in psychotic symptoms (bidirectional); lifetime use associated with earlier psychosis onset (survival analysis); mixed-effects logistic regression significant after adjustment for covariates
Confidence in the evidence
Low
The second of four GRADE levels, the effect estimate is of limited reliability.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Harm
Citations / year
★★★★★
Authors
Share
Abstract
<h4>Objective</h4>The authors examined the relationship between cannabis use and the course of illness in schizophrenia over 10 years of follow-up after first psychiatric hospitalization.<h4>Method</h4>The authors assessed 229 patients with a schizophrenia spectrum disorder five times: during the first admission and 6 months, 2 years, 4 years, and 10 years later. Ratings of cannabis use and psychiatric symptoms (psychotic, negative, disorganized, and depressive) were made at each assessment.<h4>Results</h4>The lifetime rate of cannabis use was 66.2%, and survival analysis revealed that lifetime use was associated with an earlier onset of psychosis. The rates of current use ranged from 10% to 18% across assessments. Cannabis status was moderately stable, with tetrachoric correlation coefficients between waves ranging from 0.48 to 0.78. Mixed-effects logistic regression revealed that changes in cannabis use were associated with changes in psychotic symptoms over time even after gender, age, socioeconomic status, other drug use, antipsychotic medication use, and other symptoms were controlled for. Structural equation modeling indicated that the association with psychotic symptoms was bidirectional.<h4>Conclusions</h4>Cannabis use is associated with an adverse course of psychotic symptoms in schizophrenia, and vice versa, even after taking into account other clinical, substance use, and demographic variables.
The impediment to action advances action.